Chromatin Promotes Daphne Preuss to President; Adds New Members to Board of Directors

CHICAGO, IL. (May 31, 2007) – Chromatin, Inc. announced today that Dr. Daphne Preuss has been promoted to President. In this role, she will assume responsibility for leading and managing the company and will report to Chromatin's Board of Directors. Dr. Preuss will continue in her role as Chromatin's Chief Scientific Officer. She is a founder of the company and previously served as Senior Vice President.

Roger Ganser, who has been the company's acting Chief Executive Officer since 2005, has retired from that role; Mr. Ganser will continue as Chairman of Chromatin's Board of Directors. "Since Chromatin's founding, Dr. Preuss has played an active role in the development of its patented gene stacking technology," Ganser said. "Her recent success in negotiating partnerships between Chromatin and multinational companies in the agbiotech industry, coupled with her strong management capabilities, make her an ideal choice for leading the company."

Chromatin also announced the appointments of Dr. Caroline Kovac and Dr. John Hamer to its Board of Directors; both currently serve as Managing Directors at Burrill & Co. Dr. Kovac previously held several executive management positions, including Vice President at IBM Research, where she expanded IBM's life sciences into a multi-billion dollar business, led an information technology team, established partnerships and oversaw IBM investment within the healthcare, pharmaceutical and life sciences markets. Dr. Hamer previously held several senior management positions in Paradigm Genetics Inc. including Vice President of Research, CSO and CEO; more recently he founded and served as CEO of Arête Therapeutics Inc.

"Chromatin has reached an important transition in its development," Preuss said. "As the agricultural biotechnology industry has recognized a growing need for stacking technology, Chromatin has shown that its proprietary technology can precisely and efficiently deliver gene stacks into crops. Chromatin looks forward to near-term revenue growth as a result of the increasing demand for its technology."

About Chromatin:

Chromatin, Inc. develops and markets novel proprietary technology that enables entire chromosomes to be designed and incorporated into plant cells. These mini-chromosomes can be used in any plant to simultaneously introduce multiple genes while maintaining precise control of gene expression. Chromatin's mini-chromosome technology can be used to deliver genes that benefit the agricultural, nutritional, energy, pharmaceutical, and chemical sectors.

For additional information, visit www.chromatininc.com.
Contact: Daphne Preuss, 312-455-1935x24 or Roger Ganser, 608-441-2703